Evaluation of Robot Assisted Neuro-Rehabilitation
SRT3
1 other identifier
interventional
59
1 country
1
Brief Summary
Robotic devices are capable of providing therapy to the arm of patients with weakness due to stroke. Robotic therapy improves some aspects of stroke related arm weakness, but the use of the weak arm for real life situations often remains limited. The goal of this study is to determine the best way to use robotic devices and functional task training to improve the use of the stroke affected arm for real life situations. A secondary goal of this study is to determine how or if specific areas of the brain are excited before and after training. The use of a safe and painless magnetic field directed at the brain called transcranial magnetic stimulation (TMS) will be used at set intervals to gain a better understanding of brain activity during recovery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1 stroke
Started Apr 2011
Typical duration for phase_1 stroke
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 24, 2010
CompletedFirst Posted
Study publicly available on registry
December 3, 2010
CompletedStudy Start
First participant enrolled
April 27, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 16, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2015
CompletedResults Posted
Study results publicly available
January 7, 2016
CompletedOctober 30, 2019
October 1, 2019
3.7 years
November 24, 2010
December 1, 2015
October 17, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fugl-Meyer Motor Upper Extremity Assessment
This is a stroke-specific measure of impairment of the upper extremity that has been shown to be valid and reliable with high inter-rater and test-retest reliability. It provides a direct-observational assessment of volitional movement and motor impairment related to reflexes, sensation, and abnormal synergies. Each item on the FM is rated on a three-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully). The scale ranges from 0-66 with higher scores representing less motor impairment.
Baseline, 12 week, and 24 week retention
Secondary Outcomes (3)
Motor Cortex Excitability Via Transcranial Magnetic Stimulation (TMS)
week 12
Wolf Motor Function Test (WMFT)
Baseline, 12 week, and 24 week retention
Stroke Impact Scale: Hand Subscale
Baseline, 12 week and 24 week retention
Study Arms (2)
Robot Therapy
EXPERIMENTAL12 weeks of robotic therapy
Transition to Task Training
ACTIVE COMPARATOR12 weeks of task specific practice combined with robotic therapy
Interventions
Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
Eligibility Criteria
You may qualify if:
- Adequate language, and cognitive function to participate in training, testing, and informed consent process
- The study arm of the participant will present with moderate to severe dysfunction based on Fugl-Meyer Motor Assessment range of 7 to 38
- Stroke onset greater than 6 months for ischemic stroke and greater than 1 year for hemorrhagic stroke
- Men or women over 21 years of age
You may not qualify if:
- Seizures or treatment with anticonvulsant medications within the last 10 years (This criteria does not preclude participation in the study, but does preclude participation in the TMS testing)
- Treatment with any medications known to interfere with brain stimulation: any medication with central nervous system depressant activity, including, but not limited to benzodiazepines, barbiturates, and neuroleptics (This criteria does not preclude participation in the study, but does preclude participation in the TMS testing)
- Serious complicating medical conditions, contractures or orthopedic problems in the study arm limiting the range of joint movement for the study positions
- Visual loss such that the participant cannot see the test patterns on the monitor of the training robot computer
- Botox injection to the study arm within 3 months of enrollment or during the study period
- Any change in the exercise regime involving the study arm. This includes starting any new exercise or discontinuing any current exercise regimen
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- VA Office of Research and Developmentlead
- Massachusetts Institute of Technologycollaborator
- University of Maryland, College Parkcollaborator
Study Sites (1)
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland, 21201, United States
Related Publications (1)
Conroy SS, Wittenberg GF, Krebs HI, Zhan M, Bever CT, Whitall J. Robot-Assisted Arm Training in Chronic Stroke: Addition of Transition-to-Task Practice. Neurorehabil Neural Repair. 2019 Sep;33(9):751-761. doi: 10.1177/1545968319862558. Epub 2019 Jul 22.
PMID: 31328671RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The amount of change on our primary outcome measure (FM) for this population of stroke survivors with moderated to severe upper extremity motor impairment was less than predicted (4 points vs. 8) resulting in the study groups being underpowered.
Results Point of Contact
- Title
- Dr. Christopher T. Bever, Jr. MD, MBA
- Organization
- VA Maryland Health Care System
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher T. Bever, MD
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2010
First Posted
December 3, 2010
Study Start
April 27, 2011
Primary Completion
January 16, 2015
Study Completion
January 30, 2015
Last Updated
October 30, 2019
Results First Posted
January 7, 2016
Record last verified: 2019-10